DOES: Commercializing AI in Regulated Pharma Manufacturing
商品編號：W46487
出版日期：2026/01/08
再版日期：
商品來源：
商品主題：Operations Management; Strategy
商品類型：Case (Field)
涵蓋議題：AI pharma, API manufacturing, FDA compliance, smart manufacturing, pharmaceutical reshoring, domestic drug production, personalized medicine, biotechnology startup, regulatory strategy, AI validation, supply chain resilience, digital twins, predictive ana
難易度：4 - Undergraduate/MBA
內容長度：11 頁
地域：United States
產業：Health Care Services
事件年度：2025
AWARD WINNER - 2025 Fox International Case Writing Competition
_x000D_
_x000D_
By mid-2025, Defense Operations & Engineering Inc. (DOES), a start-up based in Melbourne, Florida, and founded by Aaron Sneed, had developed a cutting-edge AI-driven smart manufacturing platform aimed at reshoring active pharmaceutical ingredient (API) production. The platform could personalize medications and optimize manufacturing in real time, but it lacked approval by the U.S. Food and Drug Administration (FDA), limiting its commercial rollout. With only US$5 million in capital and 14–18 months of runway left, Sneed faced a strategic dilemma: invest further in AI development to stay technologically ahead, prioritize regulatory compliance to speed up market entry, adopt a hybrid approach, or form partnerships to share costs and risks. The case explores the challenges of commercializing AI in a heavily regulated industry, balancing innovation with compliance, and making high-stakes decisions under financial constraints.
教學手冊：DOES: Commercializing AI in Regulated Pharma Manufacturing - Teaching Note
補充材料：
|